POST Online Media Lite Edition


NEWLY REPORTED COVID-19 CASES (11.19.2021, 4:50pm CEST, WHO):   India 11,106    Brazil 11,977    United Kingdom 46,858    Russia 37,156    Turkey 22,234    France 19,840    Argentina 1,553    Germany 52,970    Spain 3,932    Columbia 2,257    Italy 10,645    Mexico 3,836    Ukraine 20,050    Poland 23,242    Philippines 1,297    Malaysia 6,380    Netherlands 23,680    Peru 1,370    Thailand 6,855    Czechia 13,374    Canada 2,448    Romania 3,076    Chile 2,611    Serbia 3,219    Sweden 1,210    Portugal 2,398    Vietnam 10,223    Kazakhstan 1,272    Austria 14,212    Hungary 11,289    Greece 7,276    Georgia 4,278    Bulgaria 2,785    Belarus 1,844    Slovakia 7,418    Azerbaijan 2,124    Croatia 7,270    Bolivia 1,119    Ireland 4,646    Lithuania 1,847    Denmark 4,013    South Korea 3,034    Slovenia 3,662    Latvia 1,221    Laos 1,401    China 31    New Zealand 200    Australia 1,302   

England gets ready for mass COVID inoculations for 12- to 15-year-olds

Christian Fernsby |
Britain’s government said on Saturday it had told England’s health service to get ready for a mass COVID-19 vaccination programme for children aged between 12 and 15 starting in September, if vaccination experts give the green light.

Article continues below

A first vaccine dose has already been offered to all 16- and 17-year-olds in England as well as to 12- to 15-year-olds with specific underlying health conditions and those who live with someone who is immuno-suppressed.

Most children develop only mild or no symptoms from COVID-19, but they are able to spread the virus.

Britain’s health ministry said “we need to be ready to hit the ground running and start those vaccinations as soon as possible” if the government’s vaccination advisers backed extending the programme to all 12- to 15-year-olds.

The advisers are currently weighing up the possible harms and benefits of such an extension.

What to read next

Trials to find preventative COVID-19 treatments for most vulnerable to launch in UK
Moderna begins testing next-generation coronavirus vaccine
AstraZeneca's antibody drug prevents COVID-19 in high-risk groups